Protection against isoprenaline induced myocardial necroses by beta-adrenergic blocking agents.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000526:Alprenolol / Q000494:pharmacology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004983:Ethanolamines / Q000494:pharmacology; D004987:Ethers / Q000494:pharmacology; D006321:Heart / Q000187:drug effects; D007192:Indenes / Q000494:pharmacology; D007545:Isoproterenol / Q000037:antagonists & inhibitors*; D008297:Male; D009336:Necrosis / Q000139:chemically induced*; D009578:Nitrobenzenes / Q000494:pharmacology; D010096:Oxprenolol / Q000494:pharmacology; D010627:Phenethylamines / Q000494:pharmacology; D010869:Pindolol / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D013015:Sotalol / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D004987:Ethers; D007192:Indenes; D009578:Nitrobenzenes; D010627:Phenethylamines; D011412:Propanolamines; D010096:Oxprenolol; D000526:Alprenolol; D011433:Propranolol; D013015:Sotalol; D010869:Pindolol; D007545:Isoproterenol